Vaccine assays at EBF 2026

Nov 17–19, 2026 Barcelona, Spain ~800 attendees Website

6 organizations at EBF 2026 present work in vaccine assays: 4 CROs and suppliers and 2 drug developers. Between them they bring 11 presentations to the program. Most represented: Charles River Laboratories (5 on the program), Ardena (2 on the program), Institute Krems Bioanalytics (1 on the program). 4 of them have their own page in this guide. As of Oct 13, 2026.

All 63 organizations at EBF 2026 →

Showing 1–6 of 6 organizations

Organization	EBF 2026 Attendance
Charles River Laboratories Wilmington, Massachusetts	◇Sponsor
criver.com Bioanalytical CROsSponsor Contract research organization providing discovery, safety assessment and bioanalysis services for drug developers.	Talk Tue Nov 17 12:10–12:30pm Part of Session 3: Vaccines Harmonizing Validation of Vaccine Immunogenicity Assays: A Fit-for-Purpose Framework for Quantitative and Semi-Quantitative Methods Vaccines · Immunogenicity Talk Tue Nov 17 2:20–2:40pm Part of Session 4: Advancing the 3Rs: Smarter Sampling, Surrogate Matrices and Leaner Workflows Transition from Duplicate to Singlicate ADA Testing: A Retrospective Evaluation of Clinical Immunogenicity Data Immunogenicity · Sampling Talk Tue Nov 17 5–5:20pm Part of Session 8: Pharma CRO Analytical Challenges of Gas Shuttling Nanomedicine: A case study of Inter-CRO Transfer of a Bioanalytical Method for Complex Modalities New modalities Talk Wed Nov 18 12–12:20pm Part of Session 14: Rethinking ADA Assessment, Context, Evidence and Evolving Expectations - part 2 Rethinking In-Study Cut Point Application for siRNA Immunogenicity Assessment When False Positive Rates Fall Outside the Conventional Range Immunogenicity · New modalities Talk Thu Nov 19 12:10–12:30pm Part of Session 19: ADC Bioanalysis, From Community Recommendations to Complex PK Decisions Decoding ADC Complexity: Bioanalytical LC-MS Approaches and application to preclinical and clinical studies New modalities · LC–MS
Ardena Ghent, Belgium	◇Sponsor
ardena.com Bioanalytical CROsSponsor Drug development CDMO and CRO offering formulation, manufacturing and regulated bioanalysis services.	Talk Tue Nov 17 11:50am–12:10pm Part of Session 3: Vaccines Vaccine Ligand-Binding Assays for Clinical Sample Analysis: Qualification vs. Validation - A Fit-for-Purpose Approach to Dilution Series and Cut-Point Selection Vaccines · Ligand binding Talk Wed Nov 18 12–12:20pm Part of Session 13: BioA Clinic Analytical Challenges in Sphingolipid Quantification: Enabling Biomarker Discovery in Lysosomal and Neurodegenerative Disorders Biomarkers · LC–MS
Institute Krems Bioanalytics Krems, Austria	◇Sponsor
krems-bioanalytics.com Bioanalytical CROsSponsor Contract research institute of IMC Krems University of Applied Sciences running GxP immunogenicity, PK and cell-based assays for large molecules and vaccines.	Talk Thu Nov 19 10–10:20am Part of Session 15: Flow Towards Harmonization of In Vitro T-Cell Assays: Lessons from the Development of a Naïve CD4+ T-Cell Proliferation Assay Cell-based
Synexa Life Sciences Cape Town, South Africa	◇Sponsor
synexagroup.com Bioanalytical CROsSponsor Bioanalytical and biomarker lab running ligand-binding, flow cytometry and LC–MS assays for drug developers.	Talk Tue Nov 17 11:30–11:50am Part of Session 3: Vaccines When One Calibration Source Must Fit Eight Antigens: Lessons from Convalescent and Vaccinated Serum to Evaluate Vaccine-Induced Antibody Responses Vaccines
AC Immune Lausanne, Switzerland
acimmune.com Biotech Clinical-stage biotech developing vaccines and antibodies against misfolded proteins in neurodegenerative diseases such as Alzheimer's and Parkinson's.	Talk Tue Nov 17 11:10–11:30am Part of Session 3: Vaccines Active immunotherapy responder determination in a population with potential pre-existing antibodies Vaccines · Immunogenicity
MinervaX Copenhagen, Denmark
minervax.com Biotech Develops a protein-based maternal vaccine against group B streptococcus.	Talk Tue Nov 17 12:30–12:50pm Part of Session 3: Vaccines Strategies for validating functional titre based vaccine assays versus concentration based multiplex vaccine immunoassays for a multicomponent bacterial vaccine Vaccines